70829-28-6Relevant articles and documents
3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
-
Page/Page column 20, (2012/03/26)
Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is 1: a C3-8 cycloalkyl C1-4 alkyl group,2: a C7-14 aralkyl group, in which the aryl moiety thereof is
2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
-
Page 39, (2008/06/13)
The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula(I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent 0 or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.
Human glucagon receptor antagonists based on alkylidene hydrazides.
Ling, Anthony,Plewe, Michael,Gonzalez, Javier,Madsen, Peter,Sams, Christian K,Lau, Jesper,Gregor, Vlad,Murphy, Doug,Teston, Kimberly,Kuki, Atsuo,Shi, Shenghua,Truesdale, Larry,Kiel, Dan,May, John,Lakis, James,Anderes, Kenna,Iatsimirskaia, Eugenia,Sidelmann, Ulla G,Knudsen, Lotte B,Brand, Christian L,Polinsky, Alex
, p. 663 - 666 (2007/10/03)
A series of alkylidene hydrazide derivatives containing an alkoxyaryl moiety was optimized. The resulting hydrazide-ethers were competitive antagonists at the human glucagon receptor. Pharmacokinetic experiments showed fast clearance of most of the compou